Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis
European Journal of Nuclear Medicine and Molecular Imaging · 2025-01 · 52 (2) · 485-500
DOI: 10.1007/s00259-024-06922-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 23.09.2024. Verfasst von Isaac Shiri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Inselspital Bern University Hospital, University of Bern, Freiburgstrasse, Bern, CH - 3010, Switzerland. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Artificial Intelligence, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.
Abstract (Originalsprache)
Purpose
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a frequent concomitant condition in patients with severe aortic stenosis (AS), yet it often remains undetected. This study aims to comprehensively evaluate artificial intelligence-based models developed based on preprocedural and routinely collected data to detect ATTR-CM in patients with severe AS planned for transcatheter aortic valve implantation (TAVI).
Methods
In this prospective, single-center study, consecutive patients with AS were screened with [ 99m Tc]-3,3-diphosphono-1,2-propanodicarboxylic acid ([ 99m Tc]-DPD) for the presence of ATTR-CM. Clinical, laboratory, electrocardiogram, echocardiography, invasive measurements, 4-dimensional cardiac CT (4D-CCT) strain data, and CT-radiomic features were used for machine learning modeling of ATTR-CM detection and for outcome prediction. Feature selection and classifier algorithms were applied in single- and multi-modality classification scenarios. We split the dataset into training (70%) and testing (30%) samples. Performance was assessed using various metrics across 100 random seeds.
Results
Out of 263 patients with severe AS (57% males, age 83 ± 4.6years) enrolled, ATTR-CM was confirmed in 27 (10.3%). The lowest performances for detection of concomitant ATTR-CM were observed in invasive measurements and ECG data with area under the curve (AUC) < 0.68. Individual clinical, laboratory, interventional imaging, and CT-radiomics-based features showed moderate performances (AUC 0.70–0.76, sensitivity 0.79–0.82, specificity 0.63–0.72), echocardiography demonstrated good performance (AUC 0.79, sensitivity 0.80, specificity 0.78), and 4D-CT-strain showed the highest performance (AUC 0.85, sensitivity 0.90, specificity 0.74). The multi-modality model (AUC 0.84, sensitivity 0.87, specificity 0.76) did not outperform the model performance based on 4D-CT-strain only data (p-value > 0.05). The multi-modality model adequately discriminated low and high-risk individuals for all-cause mortality at a mean follow-up of 13 months.
Conclusion
Artificial intelligence-based models using collected pre-TAVI evaluation data can effectively detect ATTR-CM in patients with severe AS, offering an alternative diagnostic strategy to scintigraphy and myocardial biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Inselspital Bern University Hospital, University of Bern, Freiburgstrasse, Bern, CH - 3010, Switzerland.
- Biostatistics Unit, Department of Medical Sciences, University of Trieste, Trieste, Italy.
- University Institute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, Bern, 3010, Switzerland.
- Department of Nuclear Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Cardiology, Inselspital Bern University Hospital, University of Bern, Freiburgstrasse, Bern, CH - 3010, Switzerland. christoph.graeni@insel.ch.
Förderung
- University of Bern
Zitieren
APA
Shiri, I., Balzer, S., Baj, G., Bernhard, B., Hundertmark, M., Bakula, A., Nakase, M., Tomii, D., Barbati, G., Dobner, S., Valenzuela, W., Rominger, A., Caobelli, F., Siontis, G. C. M., Lanz, J., Pilgrim, T., Windecker, S., Stortecky, S., & Gräni, C. (2025). Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis. European Journal of Nuclear Medicine and Molecular Imaging, 52(2), 485-500. https://doi.org/10.1007/s00259-024-06922-4
Vancouver
Shiri I, Balzer S, Baj G, Bernhard B, Hundertmark M, Bakula A, et al. Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(2):485-500. doi:10.1007/s00259-024-06922-4
BibTeX
@article{Shiri2025,
author = {Shiri, Isaac and Balzer, Sebastian and Baj, Giovanni and Bernhard, Benedikt and Hundertmark, Moritz and Bakula, Adam and Nakase, Masaaki and Tomii, Daijiro and Barbati, Giulia and Dobner, Stephan and Valenzuela, Waldo and Rominger, Axel and Caobelli, Federico and Siontis, George C M and Lanz, Jonas and Pilgrim, Thomas and Windecker, Stephan and Stortecky, Stefan and Gräni, Christoph},
title = {Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {2},
pages = {485--500},
doi = {10.1007/s00259-024-06922-4}
}
EUVIMED